viewAusCann Group Holdings Ltd

AusCann Group Holdings' receipt of cannabis oils from Canopy Growth is imminent

A collaborative distribution agreement would see the two parties selling both their products into the Australian market.

Medicinal cannabis
The company will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation

Auscann Group Holdings Limited (ASX:AC8), a leading medical cannabis company, has received an import permit under its existing import licence.

Following this development, the company will soon receive finished cannabis oils from its major shareholder, Canopy Growth Corporation.

AusCann and Canopy Growth are pursuing opportunities in several key areas in Australia including the importation, distribution and local production of medical cannabis products.

AusCann managing director Elaine Darby said: “Our ongoing relationship with Canopy Growth offers major benefits for AusCann and we are very pleased to be working with Canopy Growth as the Australian market expands.

“The combination of this arrangement and our strong partnership with Tasmanian Alkaloids, positions us to be the leading supplier of affordable, effective and clinically-validated cannabinoid medicines to the Australian market and select international markets.”

AusCann's vertically integrated business model

Initial import of pain relief products

AusCann will initially import the Canopy Growth-supplied AusCann branded products for chronic and neuropathic pain control known as AC 5:5, AC 0:9.5 and AC 15:0.

Each name represents the ratio of tetrahydrocannabinol (THC) to cannabidiol (CBD) in each product.

Potential distribution of Spectrum Cannabis

Canopy Growth and AusCann are working together on developing an arrangement whereby the former will also supply AusCann with its Spectrum Cannabis branded products.

This would see AusCann distributing the product into the Australian market alongside existing AusCann products.

Spectrum Cannabis is Canopy Growth’s international medical brand, operating under a simple colour-coded system to classify its medical cannabis products.

Cashing in on distribution network

The intention is for both parties to undertake the distribution of AusCann and Spectrum products through existing and future distribution networks.

This includes AusCann’s extensive distribution network, recently broadened through the establishment of a relationship with Australian Pharmaceutical Industries (ASX:API).

READ: Auscann Group Holdings to access large Australian pharmaceutical network

Australian Pharmaceutical Industries has a network of 466 high profile brand pharmacies with representation in every state and territory in Australia.

Quick facts: AusCann Group Holdings Ltd

Price: 0.27 AUD

Market: ASX
Market Cap: $85.6 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...



Auscann targeting pain management with Australian cannabinoid products

Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....

on 6/9/18

2 min read